Navigation Links
Sensorin Raises Equity Financing to Launch Novel Industrial Sensing Venture
Date:10/21/2008

BURLINGAME, Calif., Oct. 21 /PRNewswire/ -- Sensorin, which is developing and commercializing a novel self-calibrating pH measurement platform for bioprocess applications, today announced the closing of its second round of equity funding. Use of proceeds from the financing includes product development, beta testing and launch of Sensorin's proprietary pH sensing system. Terms of the financing were not disclosed.

"Sensorin is funded by a distinguished group of individual investors with first-hand biopharmaceutical experience who are aware of the problems associated with current pH probes and who recognize the large commercial opportunity for better in-line pH measurement," said Carolyn Kahn, Ph.D., Sensorin president and CEO. "Sensorin's system represents a compelling solution for bioprocessing, including fixed and disposable fermentation systems and downstream processing."

"Improved pH control has the potential to significantly increase biopharmaceutical yields," commented Frank Jackson, former Vice President of Vacaville Product Operations for Genentech, Inc., and a Sensorin investor and advisor. "Although internally referenced approaches to measuring pH have been explored in academia, Sensorin has developed the only platform capable of in-line pH measurement without calibration, without drift and without fouling during extended periods of cell culture."

Sensorin obtained seed financing and began operations in the third quarter of 2007. The company rapidly demonstrated proof-of-concept for its proprietary technology platform, achieving this goal by the end of 2007. Sensorin is currently developing a beta version of its system for customer testing, with a prospective commercial launch in 2009.

Sensorin intends to address biologics manufacturing with its first- generation pH measurement system. The technology can be extended to other industrial pH applications, including waste-water processing and oil, gas and biofuels production.

About the Sensorin pH Measurement System

The Sensorin(TM) pH measurement system combines reusable electronic components with Sensorin's innovative solid-state pH sensor embedded in a disposable probe. Using a proprietary, internally referenced approach that is self-calibrating and drift free and does not foul in cell culture, the Sensorin system enables in-line, operator-independent pH monitoring. Sensorin's pH probes are highly accurate, precise, robust and easy to use and are designed to integrate with existing pH control equipment for bioprocessing.

Sensorin's Board of Directors

In addition to Dr. Kahn, Sensorin's board members include chairman Alan M. Mendelson, general partner of Axiom Ventures; Steve Allen, Ph.D., Managing Director of LGC Forensics and former executive of Perkin-Elmer Instruments and Mettler Toledo; George Milne, Jr., Ph.D., Executive Chairman of Rib-X, Venture Partner of Radius Ventures and former EVP of Global Research and Development of Pfizer; and Linda Rubinstein, principal of RDJ Advisors and former CFO of Solexa.

About Sensorin

Sensorin is developing and commercializing a novel, proprietary and versatile sensing technology platform. The company is initially focusing on pH measurement in high-value manufacturing, where an internally referenced, self-calibrating system without drift is advantageous. The Sensorin system is solid state, reliable, accurate and robust for deployment in process applications. The company anticipates launching its pH sensing system for biologics manufacturing in 2009. For further information, please visit http://www.sensorin.com.

For further information, contact:

Steve DiMattia

EVC Group, Inc.

917/620-0590

sdimattia@evcgroup.com


'/>"/>
SOURCE Sensorin
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Simbionix Raises Largest Amount in Companys History in Venture Capital to Accelerate Growth
2. Vista Partners Updates Coverage on Arana Therapeutics (ASX: AAH; AIM: AAHx), Raises Target Price to AU$1.65
3. Ameristar National Charity Golf Classic Raises More Than $1.1 Million for Buoniconti Fund to Cure Paralysis and Christopher & Dana Reeve Foundation
4. China Sky One Medical, Inc. Raises Guidance for 2008 Revenue and Net Income
5. MacroGenics Raises $25M in Series D-2 Financing
6. Yongye Biotechnology International Raises $9.4 Million in Private Placement
7. Proteolix Raises $79 Million in Series C Financing
8. Bacon Eating Contest Raises Money for American Heart Association
9. Baxter Raises Full-Year 2008 Outlook Following Strong Second-Quarter Financial Results
10. Pacific Biosciences Raises $100 Million to Fund Commercial Product Development
11. Alseres Pharmaceuticals, Inc. Raises $5 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... Patient ... developed with Wi-Fi connectivity to reduce the amount of wiring in a healthcare ... addition, compact mobile devices including infusion pumps, heart and hypertension monitoring, glucose monitoring, ...
(Date:5/23/2017)... ... 2017 , ... Firmex today announced the general ... for organizations to send and gather large files and confidential documents beyond the ... size limitations. , Using the same market-tested infrastructure as Firmex’s flagship Virtual ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... source of human cardiovascular cells for research and the development of cardiac ... possible to generate large numbers of cardiomyocytes (hPSC-CMs). Due to varying differentiation ...
(Date:5/23/2017)... ... May 22, 2017 , ... NetDimensions has been ranked as ... Globe™ for Corporate Learning, 2017. , Aragon Research defines Leaders as organizations who ... perform against those strategies. NetDimensions’ ranking as a Leader due to its strengths ...
Breaking Biology Technology:
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/30/2017)... Trends, opportunities and forecast in this market ... (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, vein ... use industry (government and law enforcement, commercial and retail, ... others), and by region ( North America ... Pacific , and the Rest of the World) ...
Breaking Biology News(10 mins):